AKT in cancer: new molecular insights and advances in drug development
PS Mundi, J Sachdev, C McCourt… - British journal of clinical …, 2016 - Wiley Online Library
… Aberrant overexpression of p-AKT is a common feature in both early and advanced cancers
6. AKT was … criteria of dual 70% inhibition of p-ERK and p-AKT in any of the 21 patients. The …
6. AKT was … criteria of dual 70% inhibition of p-ERK and p-AKT in any of the 21 patients. The …
Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state
…, A Carugo, J Shao, X Ma, A Harris, P Mundi… - Science translational …, 2019 - science.org
Eradicating triple-negative breast cancer (TNBC) resistant to neoadjuvant chemotherapy (NACT)
is a critical unmet clinical need. In this study, patient-derived xenograft (PDX) models of …
is a critical unmet clinical need. In this study, patient-derived xenograft (PDX) models of …
A randomized, phase II trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4/6 …
K Kalinsky, MK Accordino, C Chiuzan, PS Mundi… - 2022 - ascopubs.org
LBA1004 Background: CDK 4/6i has demonstrated benefit in progression free survival (PFS)
and overall survival (OS) in pts with HR+, HER2- MBC when combined with endocrine …
and overall survival (OS) in pts with HR+, HER2- MBC when combined with endocrine …
Targeting TRK: A fast-tracked application of precision oncology and future directions
A Kojadinovic, B Laderian, PS Mundi - Critical Reviews in Oncology …, 2021 - Elsevier
… The one exception was a patient with neuroblastoma with an ALK p.F1245 V point mutation
for whom a confirmed partial response lasted 8.3 months; this patient in fact remained on …
for whom a confirmed partial response lasted 8.3 months; this patient in fact remained on …
Randomized phase II trial of endocrine therapy with or without ribociclib after progression on cyclin-dependent kinase 4/6 inhibition in hormone receptor–positive …
…, MK Accordino, C Chiuzan, PS Mundi… - Journal of Clinical …, 2023 - ingentaconnect.com
… The P values are associated with two-way interactions tests between each subgroup and
treatment variable. CDK4/6i, cyclindependent kinase 4/6 inhibitor; Chemo, chemotherapy; …
treatment variable. CDK4/6i, cyclindependent kinase 4/6 inhibitor; Chemo, chemotherapy; …
Targeting RET alterations in cancer: Recent progress and future directions
A Shabbir, A Kojadinovic, T Shafiq, PS Mundi - Critical Reviews in …, 2023 - Elsevier
Genomic alterations in the receptor tyrosine kinase RET represent actionable driver events
in several cancer types. Activation of the kinase domain by point mutations represents a …
in several cancer types. Activation of the kinase domain by point mutations represents a …
A Transcriptome-Based Precision Oncology Platform for Patient–Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies
PS Mundi, FS Dela Cruz, A Grunn, D Diolaiti… - Cancer discovery, 2023 - AACR
Complementary precision cancer medicine paradigms are needed to broaden the clinical
benefit realized through genetic profiling and immunotherapy. In this first-in-class application, …
benefit realized through genetic profiling and immunotherapy. In this first-in-class application, …
Precision targeting with EZH2 and HDAC inhibitors in epigenetically dysregulated lymphomas
… Simultaneous mutations in EZH2 and CREBBP occur in 26 of 1,343 primary DLBCL samples
(adjusted P value < 0.001), whereas co-occurrence of mutations of EZH2 and EP300 is not …
(adjusted P value < 0.001), whereas co-occurrence of mutations of EZH2 and EP300 is not …
Emerging Therapeutic Implications of STK11 Mutation: Case Series
B Laderian, P Mundi, T Fojo, S E. Bates - The Oncologist, 2020 - academic.oup.com
… Sequencing demonstrated a concordant KRAS mutation in lung and bladder tumor as well
as an inactivating nonsense mutation in STK11 (p.E120*). The postpembrolizumab Tumor …
as an inactivating nonsense mutation in STK11 (p.E120*). The postpembrolizumab Tumor …
Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancer
…, T Cigler, P Mundi, DC Chi, A Goel, P Klein… - Breast cancer research …, 2021 - Springer
Purpose Preclinical data demonstrate STAT3 as an important regulator in HER2+ tumors, and
disruption of the IL6-JAK2-STAT-S100A8/S100A9 signaling cascade reduces HER2+ cell …
disruption of the IL6-JAK2-STAT-S100A8/S100A9 signaling cascade reduces HER2+ cell …